RPL17 and melanoma: It has been previously observed by other researchers that inhibiting or eliminating the m6A demethylase ALK-BH5 during anti-PD-1 therapy in mouse models of melanoma and colorectal cancer leads to a notable decrease in lactate levels within the TME.